A GUIDE TO HEALTHY PREGNANCY MANAGING AILMENTS AND FINDING SOLUTIONS

A_Guide_to_Healthy_Pregnancy

PREVENTION AND MANAGEMENT OF PREECLAMPSIA

Cemile Özcan Uçar

Sultanbeyli State Hospital, Department of Gynecology and Obstetrics, İstanbul, Türkiye

Özcan Uçar C. Preventing and Managing Preeclampsia in Pregnant Women. Çetin A, eds. A Guide To Healthy Pregnancy: Managing Ailments and Finding Solutions. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.51-59.

ABSTRACT

Preeclampsia is the most frequently documented gestational complication. It occurs in between 2% and 15% of all pregnancies. Hypertensive conditions in pregnancy are generally categorized into four: gestational hypertension, preeclampsia/eclampsia, chronic hypertension, and preeclampsia superimposed on chronic hypertension. Preeclampsia is a condition that carries a high risk of morbidity and mortality for both mother and fetus. Cellular and molecular mechanisms are involved in the development of preeclampsia. In general, inadequate uteroplacental blood flow with abnormal trophoblastic invasion and the resulting generalized endothelial dysfunction and vascular inflammation are thought to lead to systemic organ damage. Risk factors include race, advanced maternal age, obesity, nulliparity, multi-fetal pregnancies, and comorbid diseases. Doppler ultrasonography, mean arterial pressure and pregnancy-specific plasma protein-A can be used to predict preeclampsia. In the high-risk group, low-dose aspirin initiated in the early gestational week has been shown to be effective in preventing preeclampsia. All pathways in preeclamptic women are individualized according to the gestational week and severity of the disease. This is also the reason for the wide range of monitoring and treatment options for maternal and fetal well-being. The main aim of the follow-up and treatment is to understand the underlying pathophysiology and accordingly, to ensure that the mother and fetus are followed up and treated under appropriate conditions.

Keywords: : Preeclampsia; Severe preeclampsia; Preeclampsia prediction; Preeclampsia treatment

Referanslar

  1. Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71 Suppl 1(0 1):S18-S25. [Crossref]  [PubMed]  [PMC]
  2. Mou AD, Barman Z, Hasan M, et al. Prevalence of preeclampsia and the associated risk factors among pregnant women in Bangladesh. Sci Rep. 2021;11(1):21339. [Crossref]  [PubMed]  [PMC]
  3. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002; 287:3138. [Crossref]  [PubMed]
  4. Chang KJ, Seow KM, Chen KH. Preeclampsia: Recent advances in predicting, preventing, and managing the maternal and fetal life-threatening condition. Int. J. Environ. Res. Public. Health 2023, 20, 2994. [Crossref]  [PubMed]  [PMC]
  5. Buurma AJ, Turner RJ, Driessen JH, et al: Genetic variants in preeclampsia: a meta-analysis. Hum Reprod Update 19(3):289, 2013. [Crossref]  [PubMed]
  6. Ward K, Taylor RN: Genetic factors in the etiology of preeclampsia. In Taylor RN, Roberts JM, Cunningham FG (eds): Chelsey's Hypertensive Disorders in Pregnancyi 4th ed. Amsterdam, Academic Press, 2014. [Crossref]
  7. Staines-Urias E, Paez MC, Doyle P, et al: Genetic association studies in preeclampsia: systematic meta-analyses and field synopsis. Int J Epidemiol 41(6):1764, 2012. [Crossref]  [PubMed]
  8. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30 Suppl A(Suppl A):S32-S37. [Crossref]  [PubMed]  [PMC]
  9. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112:359. [Crossref]  [PubMed]
  10. Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant preteinuria or adverse pregnancy outcome in suspected preeclampsia: systemic review and meta-analysis. BMJ. 2012;345:e4342. [Crossref]  [PubMed]  [PMC]
  11. De Paco C, Kametas N, Renceret G, Strobl I, Nicolaides KH. Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of preeclampsia and small gestational age. Obstet Gynecol. 2008; 111:292. [Crossref]  [PubMed]
  12. Cnossen JS, Vollebregt KC, de Vrieze N, et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting preeclampsia: systematic review. BMJ. 2008;336:1117. [Crossref]  [PubMed]  [PMC]
  13. Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict preeclampsia and intrauterine growth restriction: a systemic review and bivariable meta-analysis. CMAJ. 2008;178:701. [Crossref]  [PubMed]  [PMC]
  14. Chaiworapongsa T, Romero R, Kusanovic JP, et al. Plasma soluble endoglin concentration in preeclampsia associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol. 2010;35:155. [Crossref]  [PubMed]  [PMC]
  15. Kane SC, Da Silva Costa F, Brennecke SP. New directions in the prediction of preeclampsia. Aust N Z J Obstet Gynaecol. 2014;54:101. [Crossref]  [PubMed]
  16. Poon LC, Nicolaides KH. First trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014;34:618. [Crossref]  [PubMed]
  17. Gangaram R, Naicker M, Moodley J. Accuracy of the spot urinary microalbumin:creatinine ratio and visual dipsticks in hypertensive pregnant women. Eur J Obstet Gynecol Reprod Biol. 2009;144:146. [Crossref]  [PubMed]
  18. Holzgreve W, Ghezzi F, Dİ Naro E, et al: Disturbed fetomaternal cell traffic in preeclampsia. Obstet Gynecol 91:669,1998. [Crossref]  [PubMed]
  19. Conde-Agudelo A, Romero R, Roberts JM: Tests to predict preeclampsia. Chesley's Hypertensive Disorders in Pregnancy, 4th ed. Amsterdam, Academic Press, 2014. [Link]
  20. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017;377:613. [Crossref]  [PubMed]
  21. US Preventive Services Task Forcei Davidson KW, Barry MJ, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:1186. [Crossref]  [PubMed]
  22. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216:121. [Crossref]  [PubMed]
  23. Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing preeclampsia ant its complications. Cochrane Database Syst Rev 2019; 2019. [Crossref]  [PubMed]
  24. Ayala DE, Ucieda R, Hermida RC. Chronotheraphy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30:260. [Crossref]  [PubMed]
  25. Hermida RC, Ayala DE, Calvo C, Lopez JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol 2005; 46:975. [Crossref]  [PubMed]
  26. Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321:351. [Crossref]  [PubMed]
  27. McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990; 335:1552. [Crossref]  [PubMed]
  28. Hirst J, Guyatt G, Albers GW, et al. Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:71S. [Crossref]  [PubMed]
  29. World Health Organization. WHO guideline: Calcium supplementation in pregnant women. (Accested on January 20,2015). [Link]
  30. Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008;300:2286. [Crossref]  [PubMed]
  31. Danielli M, Gillies C, Thomas RC, et al. Effects of Supervised Exercise on the Development of Hypertension Disorders of Pregnancy: A Systematic Review and Meta-Analysis. J Clin Med 2022;11. [Crossref]  [PubMed]  [PMC]
  32. Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin and Aspirin Compared With Aspirin Alone To Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. Obstet Gynecol 2016; 128:1053. [Link]
  33. Melo P, Devall A, Shennan AH, et al. Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy. A systematic review and meta-analysis. BJOG2024; 131:727. [Crossref]  [PubMed]
  34. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;(1):CD002252. [Crossref]  [PubMed]
  35. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy: Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122-1131. [PubMed]
  36. Barrilleaux PS, Martin JN Jr, Klauser CK, et al.Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: a randomized trial. Obstet Gynecol 2005; 105:843. [Crossref]  [PubMed]
  37. Fonsea JE, Mendez F, Catano C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193:1591. [Crossref]  [PubMed]
  38. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017;3:CD004454. [Crossref]  [PubMed]  [PMC]
  39. Lucas MF, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995;333:201-205.PMID:7791836. [Crossref]  [PubMed]
  40. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelets. Obstet Gynecol. 2004;103:981. [Crossref]  [PubMed]